(Q38040628)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948277%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948277%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

angiogenesis inhibitor

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948277%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Fiona J Collinson

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948277%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Jenny Seligmann

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948277%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

language of work or name

1 reference

1 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948277%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

published in

Current Oncology Reports

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948277%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948277%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948277%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

509-518

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948277%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11912-012-0274-4

12 February 2020

exact match

0 references

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer S

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Angiogenesis in normal and neoplastic ovaries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Functional significance of VEGFR-2 on ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Randomized Phase III Clinical Trial Evaluating Weekly Cisplatin for Advanced Epithelial Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Genetic epidemiology of BRCA mutations – family history detects less than 50% of the mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0274-4

Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial

21 January 2018

1 reference

12 December 2020

Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human p

1 reference

12 December 2020

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer

1 reference

12 December 2020

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

1 reference

12 December 2020

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer

1 reference

12 December 2020

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study

1 reference

12 December 2020

Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer

1 reference

12 December 2020

Advanced epithelial ovarian cancer: 1993 consensus statements

1 reference

12 December 2020

Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.

1 reference

12 December 2020

Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma

1 reference

12 December 2020

Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model

1 reference

12 December 2020

Angiogenesis in ovarian cancer

1 reference

12 December 2020

The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab

1 reference

12 December 2020

Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel

1 reference

12 December 2020

Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer

1 reference

12 December 2020

Intraperitoneal cisplatin with systemic thiosulfate protection

1 reference

12 December 2020

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

1 reference

12 December 2020

Intraperitoneal paclitaxel in the management of ovarian cancer.

1 reference

12 December 2020

The microtubule-affecting drug paclitaxel has antiangiogenic activity

1 reference

12 December 2020

Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest

1 reference

12 December 2020